Autolus therapeutics announces first patient dosed in phase 1 trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis

London and gaithersburg, md., oct. 20, 2025 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed t cell therapies, announces that the first patient has been dosed in its phase 1 bobcat trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis (pms).
PGR Ratings Summary
PGR Quant Ranking